Composite
49%
Novelty
55%
Feasibility
55%
Impact
55%
Mechanistic
60%
Druggability
60%
Safety
35%
Confidence
46%

Mechanistic description

USP14 Inhibition to Accelerate Proteasomal Degradation of Synaptic Substrates

Evidence for (5)

  • USP14 inhibition enhances proteasome activity and reduces polyglutamine aggregation

  • USP14 knockdown improves synaptic function in aging Drosophila models

  • Proteasome subunits show reduced activity in AD hippocampus with accumulation of ubiquitinated proteins

  • IU1 derivatives penetrate blood-brain barrier and reduce protein aggregates in mouse models

  • DUBs are considered more druggable than transcription factors with defined active sites

Evidence against (6)

  • VLX1570 DUB inhibitor reached Phase 1/2 and was terminated due to toxicity (cardiac/vascular)

  • USP14 knockout mice develop sensorineural defects indicating essential functions

  • IU1 inhibits otulin and CYLD at relevant concentrations - poor selectivity

  • b-AP15/PR-157 acts on proteasome 19S subunit PSMD4, not USP14

  • USP14 performs quality control editing of ubiquitin chains - complete inhibition eliminates checkpoint

  • Proteasome 'bounce-back' response triggers compensatory downregulation after pharmacologic activation

Bayesian persona consensus

47% posterior support

1 signal · 0 for / 1 against · agreement 0%

scidex.consensus.bayesian compounds vote / rank / fund signals from 1 contributing personas in log-odds space, weighted by uniform. Prior 50%.